Pfizer COVID-19 vaccine appointments are available to our patients. Sign up for Connect today to schedule your vaccination.
Joint Clinical Trials Office

Anticoagulation in Intracerebral Hemorrhage (ICH) Survivors for Stroke Prevention and Recovery (ASPIRE)

Clinical Trial Details

This study aims to determine if apixaban is superior to aspirin for prevention of stroke or hemorrhage or death in patients with recent intracerebral hemorrhage or atrial fibrillation.

Key Eligibility: 
  • Men and women 18 years or older, diagnosed with intracerebral hemorrhage and atrial fibrillation. 
  • No known allergy to aspirin or apixaban
  • Detailed eligibility will be reviewed when you contact the study team
Return to List

Study contact by location

Upper East Side - Manhattan

Contact(s)

Carla Sherman
(646) 962-8284
cas9149@med.cornell.edu

Primary Investigator(s)

Hooman Kamel, MD

Protocol ID(s)

Weill Cornell Medicine IRB #:

1909020829

ClinicalTrials.gov:

NCT03907046

Sponsor:

UO1NS106513

Status

Open to Enrollment

Age Group

Adult

Sponsor

  • National Insititute of Neurological Disorders and Stroke

Disease

Atrial Fibrillations
Intracerebral Hemorrhage